ArticleJournal of medical biochemistry2025
Chain management reduces inflammation (IL-1b, IL-6, IL-8, TNF-a, PCT) and improves vascular (NO, DD, VWF, and ET-1)/immune function in acute respiratory failure: A retrospective cohort study.
Article in Journal of medical biochemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Given the critical importance of inflammation, immune and endothelial function in acute respiratory failure (ARF), it is essential to evaluate therapeutic strategies that target these pathways to confirm their application value. This study aimed to investigate the impact of chain management (defined as a systematic protocol integrating dynamic risk assessment, standardised nursing pathways, multidisciplinary coordination, and real-time biomarker monitoring to optimise clinical decision-making) on inflammatory markers (interleukin [IL]-1b, IL-6, IL-8, tumour necrosis factor[TNF]-a, and procalcitonin[PCT]), vascular endothelial function, blood gas parameters, and T lymphocyte subsets in patients with ARF. Methods: A retrospective analysis was conducted on 101 ARF patients admitted between October 2023 and December 2024. The patients were categorised into two groups: a conventional group (55 cases, receiving standard risk warning management) and a chain group (46 cases, undergoing chain management). Levels of inflammatory factors and vascular endothelial markers (nitric oxide[NO], endothelin-1 [ET-1], etc.) were measured using enzyme-linked immunosorbent assay (ELISA), blood gas function was evaluated with a blood gas analyser, and T lymphocyte subsets (CD3+, CD4+, and CD8+) were analysed via flow cytometry. Results: Compared to the conventional group, the chain group demonstrated significantly shorter durations of mechanical ventilation and ICU stays (P<0.05). Moreover, the chain group exhibited more pronounced reductions in inflammatory factors, including IL-1b, TNF-a, and PCT (P<0.05). Improvements in vascular endothelial function were also more evident in the chain group, with higher NO levels and lower ET-1 levels (P<0.05). Additionally, the chain group achieved better blood gas outcomes, characterised by higher PaO2 and lower PaCO2 levels (P<0.05), as well as greater increases in CD3+ and CD4+ cell counts (P<0.05). Conclusions: Chain management effectively mitigates inflammatory responses and enhances vascular immune function, endothelial function in ARF patients through multi-targeted interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.